Liver Transplantation最新文献

筛选
英文 中文
Long-term maternal outcomes of pregnancy after orthotopic liver transplantation in the Netherlands: A retrospective multicenter cohort study. 荷兰正位肝移植术后孕产妇的长期预后--一项回顾性多中心队列研究。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-10 DOI: 10.1097/LVT.0000000000000477
Jildau R Meinderts, Herold J Metselaar, Bart van Hoek, Caroline M den Hoed, Douwe Rijntjes, Mariette Groenewout, Frederike G I van Vilsteren, Henk Groen, Stefan P Berger, Jelmer R Prins, Margriet F C de Jong
{"title":"Long-term maternal outcomes of pregnancy after orthotopic liver transplantation in the Netherlands: A retrospective multicenter cohort study.","authors":"Jildau R Meinderts, Herold J Metselaar, Bart van Hoek, Caroline M den Hoed, Douwe Rijntjes, Mariette Groenewout, Frederike G I van Vilsteren, Henk Groen, Stefan P Berger, Jelmer R Prins, Margriet F C de Jong","doi":"10.1097/LVT.0000000000000477","DOIUrl":"10.1097/LVT.0000000000000477","url":null,"abstract":"<p><p>Pregnancy after orthotopic liver transplantation (OLT) puts the mother, child, and transplanted organ at risk. Little is known about long-term outcomes. We performed a nationwide retrospective cohort study to evaluate short-term and long-term outcomes of post-OLT pregnancies. The secondary aim was to assess predictors for adverse pregnancy outcomes. A composite outcome of preeclampsia, preterm birth, low birth weight, and neonatal intensive care unit admission was made. Survival of women who received a transplant at <50 years of age with and without pregnancy after OLT were compared (Dutch Organ Transplantation Registry data). Descriptive statistics, regression analysis, Kaplan-Meier and log-rank analysis, and generalized estimating equation analysis were used. Among the included 70 women with 113 pregnancies >20 weeks of gestation, hypertension occurred in 20% and preeclampsia in 12%. The live birth rate was 87%; 33% were preterm, and 23% had low birth weight. Long-term follow-up (median 10 y [IQR: = 4-14]) showed small changes in serum creatinine and bilirubin ( p < 0.001). Sixteen mothers (23%) died during follow-up (median 8 y [IQR: = 4-12]), with all their children aged <18 years. No difference in survival was found when comparing women with and without pregnancy after OLT. The composite outcome occurred in 43/98 of pregnancies. Higher body mass index (BMI) and maternal age at conception increased the composite outcome risk (OR: 1.24, p < 0.01, and OR: 1.25, p = 0.01, respectively). To conclude, pregnancy after OLT does not seem to influence long-term outcomes of graft, kidney function, or patient survival in most cases. However, although pregnancy does not seem to impact survival after OLT, we do show that a substantial number of children will lose their mothers early in life. We believe this is important for pregnancy couseling of patients with an OLT and their partners.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142154488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adverse effects of graft congestion and ameliorative effects of hepatocyte growth factor after liver transplantation in rats. 大鼠肝移植后移植物充血的不良影响和肝细胞生长因子的改善作用。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-03 DOI: 10.1097/LVT.0000000000000449
Hikaru Aoki, Takashi Ito, Masaaki Hirata, Shinya Okumura, Yuki Masano, Eri Ogawa, Hironori Haga, Etsuro Hatano
{"title":"Adverse effects of graft congestion and ameliorative effects of hepatocyte growth factor after liver transplantation in rats.","authors":"Hikaru Aoki, Takashi Ito, Masaaki Hirata, Shinya Okumura, Yuki Masano, Eri Ogawa, Hironori Haga, Etsuro Hatano","doi":"10.1097/LVT.0000000000000449","DOIUrl":"10.1097/LVT.0000000000000449","url":null,"abstract":"<p><p>Living donor liver transplantation (LT) and deceased donor split-LT often result in congestion within liver grafts. The regenerative process and function of congested areas, especially graft congestion associated with LT, are not well understood. Therefore, we created new rat models with congested areas in partially resected livers and orthotopically transplanted these livers into syngeneic rats to observe liver regeneration and function in congested areas. This study aimed to compare liver regeneration and the function of congested areas after liver resection and LT, and to explore a new approach to ameliorate the adverse effects of graft congestion. Although the congested areas after liver resection regenerated normally on postoperative day 7, the congested areas after LT had poor regeneration with abscess development on postoperative day 7. Necrotic areas in congested areas were larger after LT than after liver resection on postoperative days 1, 3, and 7 ( p < 0.05, p < 0.05, and p < 0.01, respectively). Although congested areas after liver resection did not affect survival, in the LT model, the survival of rats with congested areas was significantly poorer even with larger grafts than that of rats with smaller noncongested grafts ( p = 0.04). Hepatocyte growth factor administration improved the survival rate of rats with congested grafts from 41.7% to 100%, improved the regeneration of congested areas, and significantly reduced the size of necrotic areas ( p < 0.05). Thus, congested areas in liver grafts may negatively impact recipients. Short-term administration of hepatocyte growth factor may improve postoperative outcomes of recipients with graft congestion and contribute to more effective use of liver grafts (approval number: MedKyo-23137, Institutional Ethics Committee/Kyoto University).</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial. 肝移植后阿坎酸治疗酒精使用障碍的安全性:随机对照试验。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-03 DOI: 10.1097/LVT.0000000000000475
Divya Ayyala-Somayajula, Thomas Bottyan, Suhail Shaikh, Brian P Lee, Stephanie H Cho, Jennifer L Dodge, Norah A Terrault, Hyosun Han
{"title":"Safety of acamprosate for alcohol use disorder after liver transplant: A pilot randomized controlled trial.","authors":"Divya Ayyala-Somayajula, Thomas Bottyan, Suhail Shaikh, Brian P Lee, Stephanie H Cho, Jennifer L Dodge, Norah A Terrault, Hyosun Han","doi":"10.1097/LVT.0000000000000475","DOIUrl":"10.1097/LVT.0000000000000475","url":null,"abstract":"<p><p>Acamprosate is a therapy for alcohol use disorder, but data on feasibility and safety in recipients of liver transplants are lacking. This was a single-center unblinded prospective pilot randomized controlled trial of adults (≥18 y) with liver transplant for alcohol-associated liver disease enrolled between 2021 and 2023, who were randomized 2:1 to the intervention of acamprosate (666 mg dose 3 times daily) or standard of care (SOC) over 14 weeks. Outcomes included safety (prevalence of adverse events [AEs]), feasibility (weekly survey response rate >60%), adherence (self-reported acamprosate use >60%), and efficacy (reduction in Penn Alcohol Craving Scale), and relapse-blood phosphatidylethanol (≥20 ng/mL/reported alcohol use) evaluated by standardized weekly surveys. The efficacy analysis was done in both the intention-to-treat (excluding withdrawals before medication administration) and per-protocol population (excluding withdrawals/<4 weeks participation). Of 78 participants who were approached, 30 enrolled (19 acamprosate and 11 SOC) with similar baseline characteristics. Eight participants withdrew (6 acamprosate before medication administration and 2 SOC). AEs were similar between acamprosate and SOC groups (92.3% vs. 90.0%, p > 0.99), including grade 3 AEs (53.9% vs. 60.0%, p > 0.99) with no reported grade 4/5 AEs. Survey response rates were similar in acamprosate versus SOC groups (61.0% vs. 76.0%, p = 0.19), and 69.0% were acamprosate adherents. Baseline Penn Alcohol Craving Scale values were low with no difference by the group in median absolute change in Penn Alcohol Craving Scale for intention-to-treat (0, IQR: -4 to 0 vs. 0, IQR: 0-0, p = 0.32), and per-protocol analyses (-1, IQR: -6 to 0 vs. 0, IQR: -0 to 0, p = 0.36). There was no reported or biochemical evidence of alcohol relapse. In this pilot study, preliminary data suggest that acamprosate may be safe and feasible. These data can inform larger studies and clinician efforts to address alcohol use disorder in post-liver transplant care (ClinicalTrials.gov, Number: NCT06471686).</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mapping out a Medication Adherence Promotion System (MAPS): Can it reduce graft rejection in pediatric liver transplantation? 绘制药物依从性促进系统 (MAPS):它能减少小儿肝移植中的移植物排斥反应吗?
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-02 DOI: 10.1097/LVT.0000000000000479
Sarah R Lieber, Marina Serper
{"title":"Mapping out a Medication Adherence Promotion System (MAPS): Can it reduce graft rejection in pediatric liver transplantation?","authors":"Sarah R Lieber, Marina Serper","doi":"10.1097/LVT.0000000000000479","DOIUrl":"10.1097/LVT.0000000000000479","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimization of tacrolimus in patients with HCC undergoing liver transplant: It is never too early. 肝细胞癌肝移植患者尽量少用他克莫司:为时不晚。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-02 DOI: 10.1097/LVT.0000000000000478
Manuel Luis Rodríguez-Perálvarez
{"title":"Minimization of tacrolimus in patients with HCC undergoing liver transplant: It is never too early.","authors":"Manuel Luis Rodríguez-Perálvarez","doi":"10.1097/LVT.0000000000000478","DOIUrl":"10.1097/LVT.0000000000000478","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142126123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Financial burden of cirrhosis is significantly reduced after liver transplantation. 肝移植后,肝硬化的经济负担大大减轻。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-01 Epub Date: 2024-04-25 DOI: 10.1097/LVT.0000000000000387
Daniela P Ladner, Charles F Manski
{"title":"Financial burden of cirrhosis is significantly reduced after liver transplantation.","authors":"Daniela P Ladner, Charles F Manski","doi":"10.1097/LVT.0000000000000387","DOIUrl":"10.1097/LVT.0000000000000387","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Point-of-care ultrasound in the treatment of acute kidney injury in patients with cirrhosis. 治疗肝硬化患者急性肾损伤的护理点超声。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-01 Epub Date: 2024-04-23 DOI: 10.1097/LVT.0000000000000383
Nathalie Pena Polanco, Dempsey L Hughes, Mark Ramzy, Aniruddha Srivastava, Margaret Andrzejewski, Christopher K Schott, Andres Duarte-Rojo
{"title":"Point-of-care ultrasound in the treatment of acute kidney injury in patients with cirrhosis.","authors":"Nathalie Pena Polanco, Dempsey L Hughes, Mark Ramzy, Aniruddha Srivastava, Margaret Andrzejewski, Christopher K Schott, Andres Duarte-Rojo","doi":"10.1097/LVT.0000000000000383","DOIUrl":"10.1097/LVT.0000000000000383","url":null,"abstract":"","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140867578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Indocyanine green fluorescence quantification during normothermic ex situ perfusion for the assessment of porcine liver grafts after circulatory death. 在常温原位灌注过程中对吲哚菁绿荧光进行量化,以评估猪肝脏移植后的循环死亡情况。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI: 10.1097/LVT.0000000000000416
Toru Goto, Yuki Noguchi, Ivan Linares, Laura Mazilescu, Emmanuel Nogueira, Christian Hobeika, Samrat Ray, Catherine Parmentier, Sujani Ganesh, Jathuya Peranantharuban, Harley H L Chan, Trevor Reichman, Nazia Selzner, Markus Selzner
{"title":"Indocyanine green fluorescence quantification during normothermic ex situ perfusion for the assessment of porcine liver grafts after circulatory death.","authors":"Toru Goto, Yuki Noguchi, Ivan Linares, Laura Mazilescu, Emmanuel Nogueira, Christian Hobeika, Samrat Ray, Catherine Parmentier, Sujani Ganesh, Jathuya Peranantharuban, Harley H L Chan, Trevor Reichman, Nazia Selzner, Markus Selzner","doi":"10.1097/LVT.0000000000000416","DOIUrl":"10.1097/LVT.0000000000000416","url":null,"abstract":"<p><p>Current graft evaluation during normothermic ex situ liver perfusion lacks real-time parameters for predicting posttransplant hepatocyte and biliary function. Indocyanine green (ICG) imaging has been widely used in liver surgery, enabling the visualization of hepatic uptake and excretion through bile using near-infrared light. In this research, porcine livers under various ischemic conditions were examined during a 5-hour normothermic ex situ liver perfusion procedure, introducing ICG at 1 hour through the hepatic artery. These conditions included livers from heart-beating donors, donation after circulatory death (DCD) with warm ischemic durations of 60 minutes (DCD60) and 120 minutes (DCD120), as well as interventions utilizing tissue plasminogen activator in DCD120 cases (each n = 5). Distinct hepatic fluorescence patterns correlated with different degrees of ischemic injury ( p = 0.01). Low ICG uptake in the parenchyma (less than 40% of maximum intensity) was more prevalent in DCD120 (21.4%) compared to heart-beating donors (6.2%, p = 0.06) and DCD60 (3.0%, p = 0.02). Moreover, ICG clearance from 60 minutes to 240 minutes was significantly higher in heart-beating donors (69.3%) than in DCD60 (17.5%, p < 0.001) and DCD120 (32.1%, p = 0.01). Furthermore, thrombolytic intervention using tissue plasminogen activator in DCD120 resulted in noteworthy outcomes, including significantly reduced ALP levels ( p = 0.04) and improved ICG clearance ( p = 0.02) with a trend toward mitigating fibrin deposition similar to DCD60, as well as enhancements in bile production ( p = 0.09). In conclusion, ICG fluorescence imaging during normothermic ex situ liver perfusion provides real-time classification of hepatic vascular and biliary injuries, offering valuable insights for the more accurate selection and postintervention evaluation of marginal livers in transplantation.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11332378/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The financial burden after liver transplantation is significant among commercially insured adults: A large US National Cohort. 肝移植手术后的经济负担在投保商业保险的成年人中非常严重:大型美国国家队列。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-01 Epub Date: 2023-12-18 DOI: 10.1097/LVT.0000000000000320
Sarah R Lieber, Yue Jiang, Alex R Jones, Prajwal Gowda, Nneka N Ufere, Madhukar S Patel, Tami Gurley, Alvaro Noriega Ramirez, Van M Ngo, Mary C Olumesi, Raelene E Trudeau, Jorge Marrero, Simon J Craddock Lee, Arjmand Mufti, Amit G Singal, Lisa B VanWagner
{"title":"The financial burden after liver transplantation is significant among commercially insured adults: A large US National Cohort.","authors":"Sarah R Lieber, Yue Jiang, Alex R Jones, Prajwal Gowda, Nneka N Ufere, Madhukar S Patel, Tami Gurley, Alvaro Noriega Ramirez, Van M Ngo, Mary C Olumesi, Raelene E Trudeau, Jorge Marrero, Simon J Craddock Lee, Arjmand Mufti, Amit G Singal, Lisa B VanWagner","doi":"10.1097/LVT.0000000000000320","DOIUrl":"10.1097/LVT.0000000000000320","url":null,"abstract":"<p><p>Liver transplantation (LT) is lifesaving for patients with cirrhosis; however, the resultant financial burden to patients has not been well characterized. We aimed to provide a nationally representative portrayal of patient financial burden after LT. Adult recipients of LT from 2006 to 2021 were identified using IQVIA PharMetrics® Plus for Academics-a large nationally representative claims database of commercially insured Americans. Patient financial liability (ie, what patients owe) was estimated using the difference between allowed and paid costs for adjudicated medical/pharmacy claims. Descriptive statistics were provided stratified by the financial liability group within 1 year after LT. Multivariable logistic regression modeling identified factors associated with high/extreme liability adjusting for covariates. Potential indirect costs of post-LT care were estimated based on hourly wages lost for care. Among 1412 recipients of LT, financial liability was heterogeneous-~3% had no liability and 21% had extreme liability > $10K for 1-year post-LT care; most (69%) paid between $1 and 10K, with 48% having liability >$5K. Factors associated with >$5K liability included older age, insurance/enrollment type, US region, history of HCC, and simultaneous liver-kidney transplant (for liability >$10K). Medication costs comprised ~30% of outpatient financial liability. Potential indirect costs from wages lost were $2,201-$6,073 per person, depending on an hourly wage. In a large national cohort of commercially insured recipients of LT, financial liability was highly variable across sociodemographic and clinical characteristics; nearly 1 out of 2 recipients of LT owed >$5K for 1 year of post-LT care. Transplant programs should help patients anticipate potential costs and identify vulnerable populations who would benefit from enhanced financial counseling.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182883/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138796898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An updated analysis of retransplantation following living donor liver transplantation in the United States: Insights from the latest UNOS database. 美国活体肝移植术后再次移植的最新分析:从最新的 UNOS 数据库中获得的启示。
IF 4.7 2区 医学
Liver Transplantation Pub Date : 2024-09-01 Epub Date: 2024-05-13 DOI: 10.1097/LVT.0000000000000393
Miho Akabane, Yuki Imaoka, Carlos O Esquivel, Kazunari Sasaki
{"title":"An updated analysis of retransplantation following living donor liver transplantation in the United States: Insights from the latest UNOS database.","authors":"Miho Akabane, Yuki Imaoka, Carlos O Esquivel, Kazunari Sasaki","doi":"10.1097/LVT.0000000000000393","DOIUrl":"10.1097/LVT.0000000000000393","url":null,"abstract":"<p><p>There is no recent update on the clinical course of retransplantation (re-LT) after living donor liver transplantation (LDLT) in the US using recent national data. The UNOS database (2002-2023) was used to explore patient characteristics in initial LT, comparing deceased donor liver transplantation (DDLT) and LDLT for graft survival (GS), reasons for graft failure, and GS after re-LT. It assesses waitlist dropout and re-LT likelihood, categorizing re-LT cohort based on time to re-listing as acute or chronic (≤ or > 1 mo). Of 132,323 DDLT and 5955 LDLT initial transplants, 3848 DDLT and 302 LDLT recipients underwent re-LT. Of the 302 re-LT following LDLT, 156 were acute and 146 chronic. Primary nonfunction (PNF) was more common in DDLT, although the difference was not statistically significant (17.4% vs. 14.8% for LDLT; p = 0.52). Vascular complications were significantly higher in LDLT (12.5% vs. 8.3% for DDLT; p < 0.01). Acute re-LT showed a larger difference in primary nonfunction between DDLT and LDLT (49.7% vs. 32.0%; p < 0.01). Status 1 patients were more common in DDLT (51.3% vs. 34.0% in LDLT; p < 0.01). In the acute cohort, Kaplan-Meier curves indicated superior GS after re-LT for initial LDLT recipients in both short-term and long-term ( p = 0.02 and < 0.01, respectively), with no significant difference in the chronic cohort. No significant differences in waitlist dropout were observed, but the initial LDLT group had a higher re-LT likelihood in the acute cohort (sHR 1.40, p < 0.01). A sensitivity analysis focusing on the most recent 10-year cohort revealed trends consistent with the overall study findings. LDLT recipients had better GS in re-LT than DDLT. Despite a higher severity of illness, the DDLT cohort was less likely to undergo re-LT.</p>","PeriodicalId":18072,"journal":{"name":"Liver Transplantation","volume":null,"pages":null},"PeriodicalIF":4.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信